Updates on the Management of Thyroid Cancer
Horm Metab Res DOI: 10.1055/a-1089-7870The diagnostic modalities, stratification tools, and treatment options for
patients with thyroid cancer have rapidly evolved since the development of
the American Thyroid Association (ATA) guidelines in 2015. This review
compiles newer concepts in diagnosis, stratification tools and treatment
options for patients with differentiated thyroid cancer (DTC), medullary
thyroid carcinoma (MTC) and anaplastic thyroid cancer (ATC). Newer
developments apply precision medicine in thyroid cancer patients to avoid
over-treatment in low risk disease and under-treatment in high risk disease.
Among novel patient-tailored therapies are selective RET inhibitors that
have shown efficacy in the treatment of MTC with limited systemic toxicity
compared with non-specific tyrosine kinase inhibitors. The combination of
BRAF and MEK inhibitors have revolutionized management of BRAF V600E
mutant ATC. Several immunotherapeutic agents are being actively investigated
in the treatment of all forms of thyroid cancer. In this review, we describe
the recent advances in the diagnosis and management of DTC, MTC, and ATC,
with an emphasis on novel treatment modalities. [...] © © Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents | Abstract | F...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Araque, Katherine A. Gubbi, Sriram Klubo-Gwiezdzinska, Joanna Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Endocrinology | Hormones | Thyroid | Thyroid Cancer | Toxicology